EGFR and non-small cell lung carcinoma: The 37 stage III EGFR mutant NSCLC patients underwent different treatment approaches (chemoradiation alone (n = 16); chemoradiation followed by consolidative durvalumab (n = 13); induction TKI followed by chemoradiation (n = 4); and chemoradiation followed by TKI (n = 4)), highlighting how heterogenous the management of this subpopulation is in clinical practice.